Related Experiment Videos
Mutual interaction between remacemide hydrochloride and phenytoin
J P Leach1, J Girvan, V Jamieson
1University Department of Medicine and Therapeutics, Western Infirmary, Glasgow, UK.
Epilepsy Research
|January 1, 1997
Summary
Remacemide hydrochloride slightly increases phenytoin levels in epilepsy patients but does not cause toxicity. Phenytoin, however, reduces remacemide concentrations, suggesting a manageable drug interaction.
Area of Science:
- Pharmacology
- Clinical Pharmacy
- Epilepsy Treatment
Background:
- Epilepsy management often involves combination drug therapy.
- Understanding drug-drug interactions is crucial for patient safety and treatment efficacy.
Purpose of the Study:
- To evaluate the pharmacokinetic interaction between remacemide hydrochloride and phenytoin (PHT) in epilepsy patients.
- To assess the safety and tolerability of concomitant use.
Main Methods:
- Randomized, double-blind, placebo-controlled crossover study.
- 11 epilepsy patients on phenytoin monotherapy received add-on remacemide hydrochloride or placebo.
- Plasma concentrations of PHT, remacemide, and its metabolite were measured.
Main Results:
- Remacemide hydrochloride showed a modest increase (11.5-22.2%) in PHT AUC, Cmax, and Cmin, with a significant increase in trough concentrations (20%, P=0.01).
- No PHT toxicity symptoms were reported.
- Remacemide and its metabolite concentrations were lower (40% and 30%) in PHT-treated patients compared to healthy volunteers.
Conclusions:
- Remacemide hydrochloride has a minor inhibitory effect on PHT metabolism.
- Phenytoin induces remacemide metabolism.
- These mutual interactions are modest and predictable, unlikely to impede combined clinical use.